Suven Life Sciences Limited Company Profile:
Suven Life Sciences Limited is a biopharmaceutical company, focused on discovering and developing novel pharmaceutical products, for central nervous system (“CNS”) disorders using G Protein-Coupled Receptor targets. The company’s focus has been on the discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities. The Company singularly focuses on the development of “New Chemical Entities” (“NCEs”) molecules for CNS diseases such as Alzheimer’s, various forms of Dementia, Narcolepsy, Major Depressive Disorder (“MDD”), Attention Deficient Hyperactivity Disorder (“ADHD”), Huntington’s disease, Parkinson, Bipolar disorder and different forms of neuropsychiatry disorders, gastro and pain.
Suven Life Sciences Limited Rights Issue
Wants To Apply Online 
In addition to the discovery and development of innovative molecules targeting diseases, as a service model, the company also provides a wide range of support services to global pharmaceutical and biotechnology companies by leveraging its expertise in the discovery and development of innovative molecules. The company’s integrated drug discovery and development support services helps these pharmaceutical and biotechnology companies to conduct discovery (from hit to candidate selection) and development (including the analytical and bio-analytical evaluation and stability studies).
Suven Life Sciences Limited has a professional and experienced management team and as on July 31, 2022, the company had 128 employees out of which 6 are Ph.D. holders and 94 scientists are holding master’s degrees and 3 are holding bachelor’s degrees in various disciplines of Science. As on June 30, 2022, the company has been granted 2,509 patents for 53 inventions under the drug discovery activities in various jurisdictions.
Need An Assistance:
Suven Life Sciences Rights Issue 2022 Detail:
| Issue Open | 31st October 2022 |
| Issue Close | 10th November 2022 |
| Ex-Date | 17th October 2022 |
| Record Date | 18th October 2022 |
| Listing Date | 24th November 2022 |
| Security Name | Suven Life Sciences Limited |
| Issue Size (Shares) | 72,691,239 |
| Issue Size (Amount) | ₹399.80 Crores |
| Issue Price | ₹55 per share |
| Face Value | ₹1 per share |
| Listing At | BSE, NSE |
| Terms of Payment | The full amount of Rs. 55 per share has to be paid at the time of Application. |
| Entitlement | 1 Equity Shares for every 2 Equity Shares held on the Record Date |
Suven Life Sciences financial analysis:
| Particulars | FY-22(in cr.) | FY-21(in cr.) | YoY |
| Revenue from operations | 11.84 | 13.48 | -12.1 |
| Other Income | 5.32 | 7.75 | -31.4 |
| Research & Development expenses | 106.37 | 71.03 | 49.8 |
| Employee Cost | 21.02 | 18.53 | 13.5 |
| Other expenses | 6.84 | 3.99 | 71.6 |
| EBITDA | -117.07 | -72.31 | LOSS |
| Depreciation | 4.39 | 4.35 | 1.1 |
| Interest | 0.53 | 0.82 | -35.0 |
| PBT | -122.00 | -77.47 | LOSS |
| Total tax | 0.00 | -5.32 | -100.0 |
| PAT | -122.00 | -72.15 | LOSS |
| Dep./revenue% | 37.09% | 32.25% | 15.0 |
| Int./revenue% | 4.48% | 6.05% | -26.0 |
Objects of the Issue:
The Company intends to utilize the Net Proceeds from the Issue towards the funding of the following objects:
- Meeting costs related to pharmaceutical research & development and clinical trial for molecules in the research pipelines;
- Repayment of an inter-corporate deposit availed by our Company; and
- General corporate purposes
Deployment of Net Proceeds:
| S. No. | Particulars | Amount to be
funded from the Net Proceeds (up To in cr.) |
Estimated deployment of the Net
Proceeds (in cr.) |
||
| FY-23 | FY-24 | FY-25 | |||
| 1. | Meeting costs related to pharmaceutical
research and development and clinical trial for molecules in the research pipelines; |
250.01 | 55.08 | 98.31 | 96.63 |
| 2. | Repayment of an inter-corporate deposit
availed by the Company |
50 | 50 | 0 | 0 |
| 3. | General corporate purposes | 96.99 | 29.1 | 32 | 35.88 |
| Total | 397.00 | 134.18 | 130.31 | 132.51 | |
Suven Life Sciences Rights Issue 2022 Registrar:
KFin Technologies Limited (Formerly KFin Technologies Private Limited)
Selenium, Tower B, Plot No- 31 and 32, Financial District,
Nanakramguda, Serilingampally, Hyderabad, Rangareddi 500 032,
Telangana, India
Tel: +91 40 6716 2222
Email: suven.rights@kfintech.com
Investor Grievance e-mail: einward.ris@kfintech.com
Website: www.kfintech.com
Contact Person: Mr. M. Murali Krishna
SEBI Registration No.: INR000000221